医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mauna Kea Technologies Announces Strong Presence at Asia-Pacific Digestive Week / World Congress of Gastroenterology 2013

2013年09月19日 PM02:55
このエントリーをはてなブックマークに追加


 

PARIS & SHANGHAI

Regulatory News:

Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, today announced a strong presence at the joint Asia-Pacific Digestive Week / World Congress of Gastroenterology (APDW/WCOG) 2013. 13 presentations will highlight the use of Optical Biopsy across many of the most pervasive diseases in the gastrointestinal tract.

“There is a fast-growing interest in Optical Biopsy applications in Gastroenterology in China,” said Pr. Yan-Qing Li, Chief of Gastroenterology at Shandong University, Qilu Hospital. “We’re very excited to see the broad interest generated by this key technology in our country. Several hundreds of our patients have already benefited from Optical Biopsies. The scientific exposure this year at APDW is already very significant, reflecting the high-quality clinical work performed around the world with probe-based Confocal Laser Endomicroscopy.”

Cellvizio and its miniprobes will be on display at booth #E01, together with Fujifilm China, its exclusive distributor in China.

“In China, like in the rest of world, gastroenterologists are now given the possibility to improve some of the most important procedures for their patients, thanks to Optical Biopsy. There is also clear evidence that only a short learning curve is required to interpret Optical Biopsy images and use it in routine”, said Dr. Marc Giovannini, Chief of Endoscopy at Institut Paoli-Calmettes in Marseilles, France. Dr. Giovannini will be conducting a live procedure with Cellvizio at Changhai Hospital, The Second Military Medical University, Shanghai, in a session organized by Pr. Zhao-Shen Li, Chief of Gastroenterology at Changhai Hospital. Pr. Li is also President of the Chinese Society of Digestive Endoscopy (CSDE) and Vice President of Shanghai Chinese Society of Gastroenterology (CSGE).

“The very strong exposure enjoyed by Cellvizio at APDW 2013, with 13 presentations confirming the clinical value of Optical Biopsy in gastroenterology represents a key milestone in Asia-Pacific. Our presence reflects the increasing penetration of Optical Biopsy in this region, strengthened by our expanded physical representation in Asian countries”, said Sacha Loiseau, CEO and Founder of Mauna Kea Technologies. “There is mounting evidence that Cellvizio is having an impact on how physicians in China are treating their patients and there is a fast-growing population that demands access to cutting-edge healthcare.”

The full schedule of Cellvizio optical biopsy presentations and events at APDW 2013 can be downloaded here

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio’s ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, biliary and pancreatic ducts and lungs and during fine needle aspiration procedures.

For more information on Mauna Kea Technologies, visit www.maunakeatech.com

CONTACT

Mauna Kea Technologies
Eric
Cohen
Vice President, Finance
Tel: + 33 1 70 08 09 86
investor-vpf@maunakeatech.com
France
and Europe

NewCap.
Investor
Relations and Financial Communication
Pierre Laurent / Florent Alba
Tel:
+33(0)1 44 71 94 94
maunakea@newcap.fr

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
  • Herbalife Nutrition Hong Kong and Po Leung Kuk Set New World Record in Launching Healthy Active Lifestyle Mobile App
  • Median Technologies Inks a Research Collaboration Agreement for Lung Cancer Screening Programs With Xingtai People’s Hospital, Xingtai City, China
  • Genentech’s HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds in Phase III Study in Hemophilia A
  • Orthocell Commences Treatment of Its 1,000th Patient